Here’s what you should know:
1. The deal has been met with disapproval from several shareholders. Now an unidentified top-10 investor raised concerns over the potential value the resulting combined company would have.
2. Another group of investors formed a group called “Thinking About Takeda’s Future” to raise concerns about the deal.
3. Takeda shareholders previously voted down a proposal that would have required the company to get shareholder approval for any deal with more than $8.9 billion.
4. Takeda is completing the regulatory approval process before putting the acquisition to a formal shareholder vote.
More articles on supply chain:
4 things to know about Larry Taylor, Practice Partners in Healthcare’s CEO & president
These 15 states have the most physicians
Data breaches fall 17 percent in August — Which healthcare provider was hit the worst?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.